Cyclic AMP is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-06. Numbers and descriptions here follow the published literature rather than marketing material.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
== Continuum Assumption == The continuum assumption is an idealization of continuum mechanics under which fluids can be treated as continuous, even though, on a microscopic scale, they are composed of molecules. Under the continuum assumption, macroscopic (observed/measurable) properties such as density, pressure, temperature, and bulk velocity are taken to be well-defined at "infinitesimal" volume elements—small in comparison to the characteristic length scale of the system, but large in comparison to molecular length scale. Fluid properties can vary continuously from one volume element to another and are average values of the molecular properties. The continuum hypothesis can lead to inaccurate results in applications like supersonic speed flows, or molecular flows on nano scale. Those problems for which the continuum hypothesis fails can be solved using statistical mechanics or rarefied gas dynamics. To determine whether or not the continuum hypothesis applies, the Knudsen number, defined as the ratio of the molecular mean free path to the characteristic length scale, is evaluated. Problems with Knudsen numbers below 0.1 can be evaluated using the continuum hypothesis, but molecular approach (statistical mechanics) can be applied to find the fluid motion for larger Knudsen numbers.
=== Clinical studies === Clinical trials suggest thymosin α1 may be useful in cystic fibrosis, septic shock, acute respiratory distress syndrome, peritonitis, pancreatitis, acute cytomegalovirus infection, TB, severe acute respiratory syndrome, and lung infections in critically ill patients., and for chronic hepatitis B. For hospitalized COVID-19 patients, a 2023 review concluded thymosin α1 was not effective in reducing mortality or length of hospitalization. A subsequent 2023 review contradicted this, showing a reduction in mortality but not length of stay. It has been studied for possible use in treating cancer (e.g. with chemotherapy).
=== In Anthropology === An anthropological lens challenges the idea that drug use is a universal problem, instead suggesting that perceptions of substance use and addiction depend on social, historical, political and cultural context. Drug policy and public responses vary globally, with disparities between the United Kingdom, Australia, and the United States. In the UK, drug use has become framed on crime prevention and coercion of drug users, demonstrating that definitions of harm are culturally and politically bound, questioning who health policies benefit. The USA has focused on the criminalisation of drug use, framing drug users as “morally reprehensible” and “deviant criminals”, shaping drug use as an issue of crime and social order. Australia’s 1985 adoption of harm minimisation strategies highlights that policy can shift alongside historical circumstances. The HIV/AIDS epidemic prompted a focus on safe injecting, rather than eradicating drug use. Maher and Dixon’s ethnographic research revealed that “attempts to suppress or control” drug use can shape how it is carried out, demonstrating that drug policy can shape experiences of harm. These cases corroborate Singer’s idea that drug use must be understood in its context, which challenges the narrative that drug-related harm is solely the users’ responsibility.
== X-axis: m/z (mass-to-charge ratio) == The x-axis of a mass spectrum represents a relationship between the mass of a given ion and the number of elementary charges that it carries. This is written as the IUPAC standard m/z to denote the quantity formed by dividing the mass of an ion (in daltons) by the dalton unit and by its charge number (positive absolute value). Thus, m/z is a dimensionless quantity with no associated units. Despite carrying neither units of mass nor charge, the m/z is referred to as the mass-to-charge ratio of an ion. However, this is distinct from the mass-to-charge ratio, m/Q (SI standard units kg/C), which is commonly used in physics. The m/z is used in applied mass spectrometry because convenient and intuitive numerical relationships naturally arise when interpreting spectra. A single m/z value alone does not contain sufficient information to determine the mass or charge of an ion. However, mass information may be extracted when considering the whole spectrum, such as the spacing of isotopes or the observation of multiple charge states of the same molecule. These relationships and the relationship to the mass of the ion in daltons tend toward approximately rational number values in m/z space. For example, ions with one charge exhibit spacing between isotopes of 1 and the mass of the ion in daltons is numerically equal to the m/z. The IUPAC Gold Book gives an example of appropriate use: "for the ion C7H72+, m/z equals 45.5".
Since such storing of such goods is temporal in nature and shelf life is dependent on the temperature controlled environment, they are also referred to as cargo even when in special storage to emphasize the inherent time-temperature sensitivity matrix. Temperature data loggers and time temperature indicators can record the temperature history of a shipment to help estimate their remaining shelf life. According to the USDA, "Frozen foods remain safe indefinitely". Small increases in temperature can significantly accelerate many non-biological degradation pathways because reaction rates often follow an Arrhenius-type dependence, where rate constants increase exponentially with temperature.
Sources: en.wikipedia.org
=== Separation Processes === King wrote the book Separation Processes in 1971. In the book, King presented that each of the separation processes (distillation, extraction, absorption, etc.) is a special case of a unified technology that can be described by a general set of quantitative principles. Before that, the standard separation operations were considered to be separate topics within the category of unit operations, with separate methodologies. The book was revised for a second edition in 1980. After the book went out of print, King secured the copyright back from McGraw-Hill and put it on eScholarship, where it is available open-access.
Indonesia, in recent years, has progressively liberalized its visa regime, no longer requiring visas or on-arrival visas from most nationals, while Singapore has signed visa waiver agreements with many countries in recent years and has introduced electronic visa facilities for Indians, Eastern Europeans, and mainland Chinese. This trend towards visa liberalisation in Asia is part of the regional trend toward social and economic globalisation that has been linked to heightened economic growth. Certain countries, predominantly, though not exclusively, in Western Europe and the Americas, issue working holiday visas for younger visitors to supplement their travel funds by working in minor jobs. These are especially common among members of the European Union and elsewhere in Europe. Saudi Arabia issues a special category visa for people on religious pilgrimage. Similar policies are in force in other countries with significant religious sites. Certain jurisdictions impose special visa requirements on journalists. Countries that require such visas include Cuba, China, North Korea, Saudi Arabia, America, and Zimbabwe. As a consequence of awkward border situations created by the fall of the Soviet Union, certain former members of the USSR and their neighbours maintain special visa-exemption policies for travellers transiting across international boundaries within a single country. For instance, Russia permits vehicles to transit through the Saatse Boot between the Estonian villages of Lutepää and Sesniki without a visa or border checkpoint, provided they do not stop.
Using the tool they designed virus-shaped scaffolding that can modularly attach different antigens to the surface of the DNA scaffold. Currently, MIT is working to develop optimal geometries for B cells to recognize HIV antigens. Further research has attempted to replace HIV antigens with SARS-CoV-2 and are testing whether vaccines show proper immune response from isolated B cells and in mice.
Levamisole, sold under the brand name Ergamisol among others, is a medication used to treat parasitic worm infections, specifically ascariasis and hookworm infections. It is taken by mouth. Side effects may include abdominal pain, vomiting, headache, and dizziness. Use is not recommended during breastfeeding or the third trimester of pregnancy. Serious side effects may include an increased risk of infection. It belongs to the anthelmintic class of medications. Levamisole was invented in 1966 in Belgium by Janssen Pharmaceuticals. It is on the World Health Organization's List of Essential Medicines. Levamisole is also used as a dewormer for cattle. It is also often used as a cutting agent in illegal cocaine. In February 2026, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency recommended that medicines containing levamisole be withdrawn from the EU market. This follows an EU-wide review which concluded that the benefits of these medicines no longer outweigh their risks for the treatment of parasitic worm infections in adults and children.
Sources: en.wikipedia.org
== Pre-Proto-Hassuna == More recently, the concept of a very early 'Pre-Proto-Hassuna' pottery tradition has been introduced by some scholars. This has been prompted by more recent discoveries of still earlier pottery traditions. Pre-Proto-Hassuna refers to the Late Neolithic period in Upper Mesopotamia when the ceramic containers were just being introduced. The pottery vessels were still very few in number in these early settlements. At that time, the main emphasis was on the pottery with a mineral temper, as opposed to the plant-tempered pottery which came to predominate later. The time frame for this period was about 7000-6700 BC, and at this time stone vessels and White Ware were still being used in addition to pottery. Because of the narrow local emphasis in many pottery studies as of now, these earliest pottery traditions may be known in literature as:
Venom in many snakes, such as pit vipers, affects virtually every organ system in the human body and can be a combination of many toxins, including cytotoxins, hemotoxins, neurotoxins, and myotoxins, allowing for an enormous variety of symptoms. Snake venom may cause cytotoxicity as various enzymes including hyaluronidases, collagenases, proteinases and phospholipases lead to breakdown (dermonecrosis) and injury of local tissue and inflammation which leads to pain, edema and blister formation. Metalloproteinases further lead to breakdown of the extracellular matrix (releasing inflammatory mediators) and cause microvascular damage, leading to hemorrhage, skeletal muscle damage (necrosis), blistering and further dermonecrosis. The metalloproteinase release of the inflammatory mediators leads to pain, swelling, and white blood cell (leukocyte) infiltration. The lymphatic system may be damaged by the various enzymes contained in the venom leading to edema; or the lymphatic system may also allow the venom to be carried systemically. Snake venom may cause muscle damage or myotoxicity via the enzyme phospholipase A2 which disrupts the plasma membrane of muscle cells. This damage to muscle cells may cause rhabdomyolysis, respiratory muscle compromise, or both. Other enzymes such as bradykinin potentiating peptides, natriuretic peptides, vascular endothelial growth factors, proteases can also cause hypotension or low blood pressure. Toxins in snake venom can also cause kidney damage (nephrotoxicity) via the same inflammatory cytokines.
== Function == The GLP2 receptor (GLP2R) is a G protein-coupled receptor superfamily member closely related to the glucagon receptor (GLP1 receptor). Glucagon-like peptide-2 (GLP2) is a 33-amino acid proglucagon-derived peptide produced by intestinal enteroendocrine cells. Like glucagon-like peptide-1 (GLP1) and glucagon itself, it is derived from the proglucagon peptide encoded by the GCG gene. GLP2 stimulates intestinal growth and upregulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. Moreover, GLP2 prevents intestinal hypoplasia resulting from total parenteral nutrition. GLP2R, a G protein-coupled receptor superfamily member is expressed in the gut and closely related to the glucagon receptor (GCGR) and the receptor for GLP1 (GLP1R).
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.